Amylin and Pramlintide May Increase Alzheimer's Amyloid Pathology in Mouse Model
Both amylin and the diabetes drug pramlintide increased amyloid-beta burden, synaptic loss, and brain inflammation in an Alzheimer's mouse model after 30 days of treatment.
Quick Facts
What This Study Found
Amylin and pramlintide increased amyloid-beta production by modulating APP and γ-secretase in lipid rafts, leading to increased Aβ burden, synaptic loss, and neuroinflammation in TgSwDI Alzheimer's mice.
Key Numbers
30 days IP; increased Aβ; shifted APP/gamma-secretase to lipid rafts; increased B4GALNT1, GM1, GM2 (pramlintide); synaptic loss, apoptosis, microglia activation
How They Did This
Animal study using TgSwDI transgenic mice (Alzheimer's/cerebral amyloid angiopathy model) receiving 30 days of intraperitoneal amylin or pramlintide injections, with assessment of Aβ pathology and mechanistic analysis.
Why This Research Matters
Pramlintide is used clinically for diabetes, and amylin is being explored for various metabolic conditions. If these peptides worsen Alzheimer's pathology, it has significant safety implications for millions of patients.
The Bigger Picture
This study highlights the complex relationship between diabetes and Alzheimer's disease, suggesting that some diabetes peptide therapies may have unintended neurodegenerative consequences.
What This Study Doesn't Tell Us
Transgenic Alzheimer's mouse model may not perfectly reflect human disease; 30-day treatment period; single dose level; other studies have reported opposite (protective) effects of amylin analogs.
Questions This Raises
- ?Do pramlintide users show higher rates of Alzheimer's in long-term clinical data?
- ?Why do some studies report neuroprotective effects of amylin while this study shows harm?
- ?Could dose, timing, or amylin analog modifications change the neurotoxic outcome?
Trust & Context
- Key Stat:
- Increased Aβ burden after 30 days Both amylin and pramlintide increased amyloid-beta, synaptic loss, and neuroinflammation in Alzheimer's model mice
- Evidence Grade:
- Mechanistic animal study with clear pathological findings, but contradicts some prior research showing amylin neuroprotection, and uses a transgenic model that may amplify effects.
- Study Age:
- Published in 2020; the relationship between amylin analogs and Alzheimer's remains debated, with conflicting results across different studies and models.
- Original Title:
- Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts.
- Published In:
- Scientific reports, 10(1), 3751 (2020)
- Authors:
- Mousa, Youssef M(2), Abdallah, Ihab M, Hwang, Misako, Martin, Douglas R, Kaddoumi, Amal
- Database ID:
- RPEP-05013
Evidence Hierarchy
Frequently Asked Questions
Can diabetes drugs cause Alzheimer's?
This mouse study suggests amylin and pramlintide may increase Alzheimer's-related brain changes, but human evidence is limited and other studies have shown conflicting results.
What is the connection between diabetes and Alzheimer's?
Both diseases involve misfolded proteins (amylin in diabetes, amyloid-beta in Alzheimer's). This study found that amylin peptides can worsen amyloid processing in the brain through lipid raft mechanisms.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05013APA
Mousa, Youssef M; Abdallah, Ihab M; Hwang, Misako; Martin, Douglas R; Kaddoumi, Amal. (2020). Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts.. Scientific reports, 10(1), 3751. https://doi.org/10.1038/s41598-020-60664-5
MLA
Mousa, Youssef M, et al. "Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts.." Scientific reports, 2020. https://doi.org/10.1038/s41598-020-60664-5
RethinkPeptides
RethinkPeptides Research Database. "Amylin and pramlintide modulate γ-secretase level and APP pr..." RPEP-05013. Retrieved from https://rethinkpeptides.com/research/mousa-2020-amylin-and-pramlintide-modulate
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.